Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Beckmann

Showing results (71-80 of 88) with videos related to

Pageof 9
Sort By:
Blood|May 15, 1994
Cloning of the human homologue of the murine flt3 ligand: a growth factor for early hematopoietic progenitor cellsS D Lyman, L James, L Johnson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 9, 2017
The Checkpoint Kinase 1 Inhibitor Prexasertib Induces Regression of Preclinical Models of Human NeuroblastomaCaitlin D Lowery, Alle B VanWye, Michele Dowless, et al.
Journal of Immunology (Baltimore, Md. : 1950)|June 1, 1990
Monoclonal antibodies block murine IL-4 receptor functionM P Beckmann, K A Schooley, B Gallis, et al.
Molecular Cancer Therapeutics|August 15, 2014
The CDK4/6 inhibitor LY2835219 overcomes vemurafenib resistance resulting from MAPK reactivation and cyclin D1 upregulationVipin Yadav, Teresa F Burke, Lysiane Huber, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 23, 2014
Semi-mechanistic pharmacokinetic/pharmacodynamic modeling of the antitumor activity of LY2835219, a new cyclin-dependent kinase 4/6 inhibitor, in mice bearing human tumor xenograftsSonya C Tate, Shufen Cai, Rose T Ajamie, et al.
The Journal of Biological Chemistry|April 5, 1993
Importance of the amino terminus of the interleukin-8 receptor in ligand interactionsR B Gayle, P R Sleath, S Srinivason, et al.
Oncogene|December 22, 1999
Conditional transformation of rat embryo fibroblast cells by a cyclin D1-cdk4 fusion geneR N Rao, N B Stamm, K Otto, et al.
Annual Review of Immunology|January 11, 1990
Lymphokine control of in vivo immunoglobulin isotype selectionF D Finkelman, J Holmes, I M Katona, et al.
Oncotarget|October 21, 2017
Preclinical characterization of abemaciclib in hormone receptor positive breast cancerRaquel Torres-Guzmán, Bruna Calsina, Ana Hermoso, et al.
Oncogene|October 24, 2017
RAF inhibitor LY3009120 sensitizes RAS or BRAF mutant cancer to CDK4/6 inhibition by abemaciclib via superior inhibition of phospho-RB and suppression of cyclin D1S-H Chen, X Gong, Y Zhang, et al.
Pageof 9

Showing results (71-80 of 88) with videos related to

Sort By:
Pageof 9
Blood|May 15, 1994
Cloning of the human homologue of the murine flt3 ligand: a growth factor for early hematopoietic progenitor cellsS D Lyman, L James, L Johnson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 9, 2017
The Checkpoint Kinase 1 Inhibitor Prexasertib Induces Regression of Preclinical Models of Human NeuroblastomaCaitlin D Lowery, Alle B VanWye, Michele Dowless, et al.
Journal of Immunology (Baltimore, Md. : 1950)|June 1, 1990
Monoclonal antibodies block murine IL-4 receptor functionM P Beckmann, K A Schooley, B Gallis, et al.
Molecular Cancer Therapeutics|August 15, 2014
The CDK4/6 inhibitor LY2835219 overcomes vemurafenib resistance resulting from MAPK reactivation and cyclin D1 upregulationVipin Yadav, Teresa F Burke, Lysiane Huber, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 23, 2014
Semi-mechanistic pharmacokinetic/pharmacodynamic modeling of the antitumor activity of LY2835219, a new cyclin-dependent kinase 4/6 inhibitor, in mice bearing human tumor xenograftsSonya C Tate, Shufen Cai, Rose T Ajamie, et al.
The Journal of Biological Chemistry|April 5, 1993
Importance of the amino terminus of the interleukin-8 receptor in ligand interactionsR B Gayle, P R Sleath, S Srinivason, et al.
Oncogene|December 22, 1999
Conditional transformation of rat embryo fibroblast cells by a cyclin D1-cdk4 fusion geneR N Rao, N B Stamm, K Otto, et al.
Annual Review of Immunology|January 11, 1990
Lymphokine control of in vivo immunoglobulin isotype selectionF D Finkelman, J Holmes, I M Katona, et al.
Oncotarget|October 21, 2017
Preclinical characterization of abemaciclib in hormone receptor positive breast cancerRaquel Torres-Guzmán, Bruna Calsina, Ana Hermoso, et al.
Oncogene|October 24, 2017
RAF inhibitor LY3009120 sensitizes RAS or BRAF mutant cancer to CDK4/6 inhibition by abemaciclib via superior inhibition of phospho-RB and suppression of cyclin D1S-H Chen, X Gong, Y Zhang, et al.
Pageof 9